Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 5/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.46 |
| ▸ | PDE4A | P27815 | 8/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 8/20 | 0.46 |
| ▸ | ACACA | Q13085 | 7/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18909798 | 0.89 | PDE4D (0.45) | ACACBPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL18821278 | 0.88 | ACACB (0.43) | ACACBPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL18908241 | 0.86 | ACACA (0.39) | ACACBPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL18907743 | 0.86 | ACACA (0.39) | ACACBPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL18909759 | 0.82 | PDE4D (0.51) | ACACBPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL18908197 | 0.82 | ACACB (0.35) | ACACBACACA | |
| SCHEMBL18908167 | 0.82 | ACACB (0.49) | ACACBPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL18907641 | 0.81 | ACACB (0.53) | ACACBPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL16245922 | 0.81 | ACACB (0.53) | ACACBPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL18908199 | 0.80 | PTGDR2 (0.36) | ACACBPDE4DPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10800791-B2 | Triazole ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2020-10-13 | — | — | US | disclosed |
| US-20190241582-A1 | Triazole ACC inhibitors and uses thereof | Nimbus Apollo, Inc. | 2019-08-08 | — | — | US | disclosed |
| US-20170166584-A1 | TRIAZOLE ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2017-06-15 | — | — | US | disclosed |
| US-20170166584-A1 | TRIAZOLE ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2017-06-15 | — | — | US | disclosed |
| WO-2017091617-A1 | TRIAZOLE ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC (US) | 2017-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241582-A1 | Triazole ACC inhibitors and uses thereof | ACACA, ACACB, ACAT1 | ACACB 2/4885PDE4D 2986/4885PDE4A 3157/4885 |
| US-10800791-B2 | Triazole ACC inhibitors and uses thereof | ACACA, ACACB, ACAT1 | ACACB 2/4885PDE4D 2986/4885PDE4A 3157/4885 |
| US-20170166584-A1 | TRIAZOLE ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT1 | ACACB 2/4885PDE4D 2986/4885PDE4A 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.